Skip to main content

Doxorubicin Liposomal Dosage

Medically reviewed by Drugs.com. Last updated on Dec 15, 2020.

Applies to the following strengths: 2 mg/mL

Usual Adult Dose for Ovarian Cancer

NOTE: Several dosage regimens exist for this drug. The information presented here is manufacturer recommended dosing. Some cancers are more responsive to this drug than others. Always consult institutional protocol.

50 mg/m2 IV at an initial rate of 1 mg/min to minimize the risk of infusion reactions; if no infusion-related adverse events are observed, the rate of infusion can be increased to complete administration over 60 minutes; the patient should be dosed once every 28 days until disease progression or unacceptable toxicity

Use: For the treatment of patients with ovarian cancer whose disease has progressed or recurred after platinum-based chemotherapy

Usual Adult Dose for Kaposi's Sarcoma

NOTE: Several dosage regimens exist for this drug. The information presented here is manufacturer recommended dosing. Some cancers are more responsive to this drug than others. Always consult institutional protocol.

20 mg/m2 IV at an initial rate of 1 mg/min to minimize the risk of infusion reactions; if no infusion-related adverse events are observed, the rate of infusion can be increased to complete administration over 60 minutes; the patient should be dosed once every 21 days until disease progression or unacceptable toxicity

Use: For AIDS-related Kaposi's sarcoma after failure of prior systemic chemotherapy or intolerance to such therapy

Usual Adult Dose for Multiple Myeloma

NOTE: Several dosage regimens exist for this drug. The information presented here is manufacturer recommended dosing. Some cancers are more responsive to this drug than others. Always consult institutional protocol.

30 mg/m2 IV at an initial rate of 1 mg/min to minimize the risk of infusion reactions; if no infusion-related adverse events are observed, the rate of infusion can be increased to complete administration over 60 minutes on day 4 of each 21-day cycle for 8 cycles or until disease progression or unacceptable toxicity; administer this drug after bortezomib on day 4 of each cycle

Use: This drug in combination with bortezomib, is indicated for the treatment of patients with multiple myeloma who have not previously received bortezomib and have received at least one prior therapy

Renal Dose Adjustments

No adjustment recommended.

Liver Dose Adjustments

This drug is eliminated in large part by the liver. Reduce the dose for serum bilirubin of 1.2 mg/dL or higher.

Dose Adjustments

DO NOT INCREASE THE DOSE OF THIS DRUG AFTER A DOSE REDUCTION FOR TOXICITY.

For neuropathic pain or peripheral neuropathy, no dosage adjustments are required for this drug.

Refer to bortezomib manufacturer prescribing information for dose adjustments.

HAND-FOOT SYNDROME (HFS):
GRADE 1 (mild erythema, swelling, or desquamation not interfering with daily activities):

  • If no previous Grade 3 or 4 HFS: No dose adjustment recommended.
  • If previous Grade 3 or 4 HFS: Delay dose up to 2 weeks, then decrease dose by 25%.
GRADE 2 (erythema, desquamation, or swelling interfering with, but not precluding normal physical activities; small blisters or ulcerations less than 2 cm in diameter):
  • Discontinue therapy if no resolution after 2 weeks.
  • And no previous Grade 3 or 4 HFS: Continue therapy at previous dose.
  • Discontinue therapy if there is no resolution after 2 weeks.
  • And no previous Grade 3 or 4 stomatitis: Resume therapy at previous dose.
  • Discontinue therapy if there is no resolution after 2 weeks.
  • And no previous Grade 3 or 4 stomatitis: Resume therapy at previous dose.

Frequently asked questions

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.